These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18783948)

  • 1. Structure-activity relationship of ortho- and meta-phenol based LFA-1 ICAM inhibitors.
    Lin EY; Guckian KM; Silvian L; Chin D; Boriack-Sjodin PA; van Vlijmen H; Friedman JE; Scott DM
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5245-8. PubMed ID: 18783948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of a series of meta aniline-based LFA-1 ICAM inhibitors.
    Guckian KM; Lin EY; Silvian L; Friedman JE; Chin D; Scott DM
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5249-51. PubMed ID: 18778938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Benzoyl amino acids as ICAM/LFA-1 inhibitors. Part 2: structure-activity relationship of the benzoyl moiety.
    Burdick DJ; Marsters JC; Aliagas-Martin I; Stanley M; Beresini M; Clark K; McDowell RS; Gadek TR
    Bioorg Med Chem Lett; 2004 May; 14(9):2055-9. PubMed ID: 15080978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,4-Diazepane-2-ones as novel inhibitors of LFA-1.
    Wattanasin S; Albert R; Ehrhardt C; Roche D; Sabio M; Hommel U; Welzenbach K; Weitz-Schmidt G
    Bioorg Med Chem Lett; 2003 Feb; 13(3):499-502. PubMed ID: 12565959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold.
    Dodd DS; Sheriff S; Chang CJ; Stetsko DK; Phillips LM; Zhang Y; Launay M; Potin D; Vaccaro W; Poss MA; McKinnon M; Barrish JC; Suchard SJ; Murali Dhar TG
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1908-11. PubMed ID: 17291752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.
    Hanessian S; Therrien E; van Otterlo WA; Bayrakdarian M; Nilsson I; Fjellström O; Xue Y
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1032-6. PubMed ID: 16290930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin-derived 1,3-oxazinan-2-ones as submicromolar inhibitors of LFA-1/ICAM-1 interaction: stabilization of the metabolically labile vanillyl side chain.
    Ullrich T; Baumann K; Welzenbach K; Schmutz S; Camenisch G; Meingassner JG; Weitz-Schmidt G
    Bioorg Med Chem Lett; 2004 May; 14(10):2483-7. PubMed ID: 15109637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary metabolites from marine cyanobacteria and algae inhibit LFA-1/ICAM-1 mediated cell adhesion.
    Takamatsu S; Nagle DG; Gerwick WH
    Planta Med; 2004 Feb; 70(2):127-31. PubMed ID: 14994189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.
    Walker DP; Bi FC; Kalgutkar AS; Bauman JN; Zhao SX; Soglia JR; Aspnes GE; Kung DW; Klug-McLeod J; Zawistoski MP; McGlynn MA; Oliver R; Dunn M; Li JC; Richter DT; Cooper BA; Kath JC; Hulford CA; Autry CL; Luzzio MJ; Ung EJ; Roberts WG; Bonnette PC; Buckbinder L; Mistry A; Griffor MC; Han S; Guzman-Perez A
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6071-7. PubMed ID: 18951788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-alpha]imidazol-2-one derivatives.
    Wu JP; Emeigh J; Gao DA; Goldberg DR; Kuzmich D; Miao C; Potocki I; Qian KC; Sorcek RJ; Jeanfavre DD; Kishimoto K; Mainolfi EA; Nabozny G; Peng C; Reilly P; Rothlein R; Sellati RH; Woska JR; Chen S; Gunn JA; O'Brien D; Norris SH; Kelly TA
    J Med Chem; 2004 Oct; 47(22):5356-66. PubMed ID: 15481974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
    Deak HL; Newcomb JR; Nunes JJ; Boucher C; Cheng AC; DiMauro EF; Epstein LF; Gallant P; Hodous BL; Huang X; Lee JH; Patel VF; Schneider S; Turci SM; Zhu X
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1172-6. PubMed ID: 18083554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual screening leads to the discovery of an effective antagonist of lymphocyte function-associated antigen-1.
    Shoda M; Harada T; Yano K; Stahura FL; Himeno T; Shiojiri S; Kogami Y; Kouji H; Bajorath J
    ChemMedChem; 2007 Apr; 2(4):515-21. PubMed ID: 17340656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure-activity relationship.
    Burdick DJ; Paris K; Weese K; Stanley M; Beresini M; Clark K; McDowell RS; Marsters JC; Gadek TR
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1015-8. PubMed ID: 12643901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.
    Lo HY; Bentzien J; Fleck RW; Pullen SS; Khine HH; Woska JR; Kugler SZ; Kashem MA; Takahashi H
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6218-21. PubMed ID: 18930400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic control of allosteric antagonism of leukocyte function antigen-1 and intercellular adhesion molecule-1 interaction.
    Nam K; Maiorov V; Feuston B; Kearsley S
    Proteins; 2006 Aug; 64(2):376-84. PubMed ID: 16705652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.
    Zhong M; Shen W; Barr KJ; Arbitrario JP; Arkin MR; Bui M; Chen T; Cunningham BC; Evanchik MJ; Hanan EJ; Hoch U; Huen K; Hyde J; Kumer JL; Lac T; Lawrence CE; Martell JR; Oslob JD; Paulvannan K; Prabhu S; Silverman JA; Wright J; Yu CH; Zhu J; Flanagan WM
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5269-73. PubMed ID: 20655213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and functional evaluation of leukocyte function associated antigen-1 antagonists in early and late stages of cancer development.
    San Sebastián E; Zimmerman T; Zubia A; Vara Y; Martin E; Sirockin F; Dejaegere A; Stote RH; Lopez X; Pantoja-Uceda D; Valcárcel M; Mendoza L; Vidal-Vanaclocha F; Cossío FP; Blanco FJ
    J Med Chem; 2013 Feb; 56(3):735-47. PubMed ID: 23339734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and SAR of diarylsulfide cyclopropylamide LFA-1/ICAM-1 interaction antagonists.
    Link JT; Sorensen B; Liu G; Pei Z; Reilly EB; Leitza S; Okasinski G
    Bioorg Med Chem Lett; 2001 Apr; 11(8):973-6. PubMed ID: 11327603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.
    Zhong M; Hanan EJ; Shen W; Bui M; Arkin MR; Barr KJ; Evanchik MJ; Hoch U; Hyde J; Martell JR; Oslob JD; Paulvannan K; Prabhu S; Silverman JA; Wright J; Yu CH; Zhu J; Flanagan WM
    Bioorg Med Chem Lett; 2011 Jan; 21(1):307-10. PubMed ID: 21109434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.